Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HLA-A*2402-restricted URLC10 + CDCA1 + VEGFR1 + VEGFR2
- Development stage
- Unknown
- Lead developer
- The University of Tokyo
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
A cancer vaccine composed of four synthetic peptides—URLC10, CDCA1, vascular endothelial growth factor receptor 1 (VEGFR1), and vascular endothelial growth factor receptor 2 (VEGFR2)—each restricted to the human leukocyte antigen allele HLA-A*2402. This multipeptide formulation is designed to stimulate cytotoxic T lymphocyte responses against tumor-associated antigens expressed in various cancers. The mechanism involves presenting these peptide epitopes on tumor cells via MHC class I molecules to activate specific anti-tumor immune responses. It has been investigated primarily as an immunotherapeutic approach for advanced or recurrent non-small cell lung cancer and other solid tumors[8][2][1].
- Other names
- HLA-A24.2 multi-peptide vaccine (URLC10, CDCA1, VEGFR1, VEGFR2)
02
Targets
NUF2 (Cell division cycle associated 1 protein)HLA-A*24 (Major histocompatibility complex class I molecule presenting MAGE-A4 peptide)CD8A (CD8 alpha/beta Coreceptor)VEGFR-1 (Vascular endothelial growth factor receptor 1)LY6K (Lymphocyte antigen 6 complex locus protein K)
Beyond the preview
Go deeper on HLA-A*2402-restricted URLC10 + CDCA1 + VEGFR1 + VEGFR2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLA-A*2402-restricted URLC10 + CDCA1 + VEGFR1 + VEGFR2.